Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson's disease and the neuroprotective role of coenzyme Q10

Brain Research Bulletin

Volumn 70, Issue 1, 2006, Pages 22-32

  Sharma, Sushil K ^a   El ReFaey, Hesham ^a   Ebadi, Manuchair ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

18F DOPA; Coenzyme Q10; Complex 1; Metallothionein; MicroPET; Parkinson's disease

Indexed keywords

DOPA; FLUORINE 18; FLUORODOPA F 18; METALLOTHIONEIN; NEUROPROTECTIVE AGENT; RADIOPHARMACEUTICAL AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; UBIDECARENONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME SYNTHESIS; GENETIC ENGINEERING; GENOTYPE; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MALE; MITOCHONDRIAL MEMBRANE; MOTOR PERFORMANCE; MOUSE STRAIN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TRANSGENIC MOUSE;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIHYDROXYPHENYLALANINE; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT COMPLEX I; FLUORINE RADIOISOTOPES; HUMANS; MALE; METALLOTHIONEIN; MICE; MICE, INBRED C57BL; MICE, NEUROLOGIC MUTANTS; MICE, TRANSGENIC; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; STATISTICS; TISSUE DISTRIBUTION; UBIQUINONE;

EID: 33646864094     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2005.11.019     Document Type: Article

References (50)

1. Beal M.F. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neurol. 44 (1998) S110-S114
2. 10 administration and its potential in treatment of neurodegenerative disorders. Biofactors 9 (1999) 261-266
3. 10 as a possible treatment for neurodegenerative diseases. Free Radic. Res. 36 (2002) 455-460
4. 10 attenuates the 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 783 (1998) 109-114
5. 2+ release. Free Radic Biol. Med. 29 (2000) 343-348
6. Cai L., Klein J.B., and Kang Y.J. MT inhibits peroxynitrite-induced DNA and lipoprotein damage. J. Biol. Chem. 275 (2001) 38957-38960
7. Dakshinamurti K., Sharma S.K., Sundaram K., and Watanabe T. Hippocampal changes in developing postnatal mice following intrauterine exposure to domoic acid. J. Neurosci. 13 (1993) 4486-4495
8. Dawson V.L., and Dawson T.M. Nitric oxide in neurodegeneration. Prog. Brain Res. 118 (1998) 215-229
9. Ebadi M., Brown-Borg H., El ReFaey H., Singh B., Shavali S., and Sharma S.K. Metallothionein-mediated neuroprotection in mouse models of Parkinson's disease. Brain Res. 134 (2005) 67-75
10. 10) and mitochondria in oxidative stress of Parkinson's disease. Biol. Signal. Recept. 10 (2001) 224-253
11. Ebadi M., Hiramatsu M., Burke W.J., Folks D.G., and El-Sayed M.A. MT isoforms provide neuroprotection against 6-hydroxy-dopamine-generated hydroxyl radicals and superoxide anions. Proc. West. Pharmacol. Soc. 41 (1998) 155-158
12. Ebadi M., Leuschen M.P., El ReFaey H., Hamada F.M., and Rojas P. The antioxidant properties of zinc and metallothionein. Neurochem. Int. 29 (1996) 159-166
13. Ebadi M., Pfeiffer R.F., Murrin L.C., and Shiraga H. Metallothionein and oxidation reactions in Parkinson's disease. Proc. West. Pharmacol. Soc. 34 (1991) 285-290
14. Ebadi M., and Sharma S. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Antiox. Redox Signal. 5 (2003) 319-335
15. Ebadi M., Sharma S., Amornpan A., and Maanum S. Weaver mutant mouse in progression of neurodegeneration. In: Ebadi M., and Pfeffier R. (Eds). Parkinson's Disease (2005), CRC Press, New York 537-555 (Chapter 43)
16. Ebadi M., Sharma S.K., Ghafourifar P., Brown-Borg H., and El ReFaey H. Peroxynitrite in the pathogenesis of Parkinson's disease and the neuroprotective role of metallothioneins. Meth. Enzymol. 396 (2005) 276-298
17. Ebadi M., Sharma S., Muralikrishnan D., Shavali S., Eken J., Sangchot P., Chetsawang B., and Brekke L. Metallothionein provides ubiquinone-mediated neuroprotection in Parkinson's disease. Proc. West. Pharmacol. Soc. 45 (2002) 1-3
18. Ebadi M., Sharma S., Shavali S., and El ReFaey H. Neuroprotective actions of Selegiline. J. Neurosci. Res. 67 (2002) 285-289
19. Ebadi M., Sharma S., Shavali S., Sangchot P., and Brekke L. The multiple actions of Selegiline. Proc. West. Pharmacol. Soc. 45 (2002) 106-107
20. 10 inhibits mitochondrial complex-1 down-regulation and nuclear factor-kappa B activation. J. Cell. Mol. Med. 8 (2004) 213-222
21. Ebadi M., Sharma S.K., Wanpen S., and Shavali S. Metallothionein isoforms attenuate peroxynitrite-induced oxidative stress in Parkinson's disease. In: Ebadi M., and Pfeffier R. (Eds). Parkinson's Disease (2005), CRC Press, New York 479-499 (Chapter 39)
22. Fosslien E. Mitochondrial medicine-molecular pathology of defective oxidative phosphorylation. Ann. Clin. Lab. Sci. 31 (2001) 25-67
23. Gerlach M., Blum-Degen D., Lan J., and Riederer P. Nitric oxide in the pathogenesis of Parkinson's disease. Adv. Neurol. 80 (1999) 239-245
24. Ghafourifar P., Bringold U., and Klein S.D. Mitochondrial nitric oxide Synthase, oxidative stress and apoptosis. Biol. Signal. Recept. 10 (2001) 57-65
25. 10 in Parkinson's disease. J. Neural. Transm. 107 (2000) 41-48
26. Hirsch E.C., and Hunot S. Nitric oxide, glial cells and neuronal degeneration in Parkinsonism. Trends Pharmacol. Sci. 21 (2002) 163-165
27. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debre P., Agid Y., and Dugas B. Hirsch FcepsilonRII/CD23 is expressed in Parkinson's disease and induces in vitro production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 19 (1999) 344-347
28. Imam S.Z., El-Yazal J., Newport G.D., Itzhak Y., Cadet J.L., Slikker Jr. W., and Ali S.F. Methamphetamine-induced dopamine neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. Ann. NY Acad. Sci. 939 (2002) 366-380
29. Rojas P., Cerutis D.R., Happe H.K., Murrin L.C., Hao R., Pfeiffer R.F., and Ebadi M. 6-Hydroxy-dopamine-mediated induction of rat brain MT-I mRNA. Neurotoxicology 17 (1996) 323-334
30. Rojas P., Hidalgo J., Ebadi M., and Rios C. Changes of MT-I+II proteins in the brain after 1-methyl-4-phenylpyridinium administration in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 24 (2001) 143-154
31. Rojas P., Rojas-Castaneda J., Vigueras R.M., Habeebu S.S., Rojas C., Rios C., and Ebadi C.M. MPTP decreases MT-I mRNA in mouse striatum. Neurochem. Res. 5 (2001) 503-509
32. Rosenberg R.N. Mitochondrial therapy for Parkinson disease. Arch. Neurol. 59 (2002) 1523
33. Sangchot P., Sharma S., Chetsawang B., Govitrapong P., and Ebadi M. Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and α-synuclein translocation in SK-N-SH cells in culture. Dev. Neurosci. 24 (2002) 143-153
34. Schulz J.B., Matthews R.T., Klockgether T., Dichgans J., and Beal M.F. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol. Cell. Biochem. 174 (1997) 193-197
35. Schulz J.B., Matthews R.T., Muqit M.M., Brown S.E., and Beal M.F. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64 (1995) 936-939
36. Sharma S.K., and Ebadi M. Metallothionein attenuates 3-morpholinosydnonimine (SIN-1)-induced oxidative and nitrative stress in dopaminergic neurons. Antioxid. Redox Signal. 5 (2003) 231-264
37. Sharma S.K., and Ebadi M. An improved method for analyzing coenzyme Q homologues and multiple detection of rare biological samples. J. Neurosci. Meth. 137 (2004) 1-9
38. 18F-DOPA in weaver mutant mice, Mol. Brain Res. 139 (2005) 23-30
39. 10 in Parkinson's disease. Meth. Enzymol. 382 (2004) 488-509
40. Sharma S.K., Sangchot P., and Ebadi M. MT Gene manipulation influences striatal mitochondrial ubiquinones and MPTP-induced neurotoxicity in dopaminergic neurons. World Cong. Pharmacol. 14 (2002) 106-107
41. Sharma S.K., Shavali S., El ReFaey H., and Ebadi M. Inhibition of α-Syn nitration and perinuclear aggregation by antioxidants in metallothionein transgenic and aging RhO (mgko) dopaminergic neurons. FASEB J. 16 (2002) 68611
42. 10 in Parkinsonian patients. Neurology 50 (1998) 793-795
43. 10 levels correlate with the activities of complexes I and II/III in mitochondria from Parkinsonian and nonParkinsonian subjects. Ann. Neurol. 42 (1997) 261-264
44. 10 in early Parkinson's disease. Arch. Neurol. 59 (2002) 1523
45. 10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59 (2002) 1541-1550
46. Stamler J.S., Singel D.L., and Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 258 (1998) 1898-1902
47. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci. 22 (2002) 1763-1771
48. Youdim M.B., Ben-Shachar D., Eshel G., Finberg J.P., and Riederer P. The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease. Adv. Neurol. 60 (1993) 259-266
49. Youdim M.B., and Lavie L. Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease. Life Sci. 55 (1994) 2077-2082
50. Youdim M.B., Lavie L., and Riederer P. Oxygen free radicals and neurodegeneration in Parkinson's disease: a role for nitric oxide. Ann. NY Acad. Sci. 738 (1994) 64-68